Ping Liu, Zhaohui Meng, Lei Zhang, Guangjuan Li, Hui Huang
{"title":"Effect of HDAC4 regulation of β-catenin signaling pathway on cardiac injury in spontaneously hypertensive rats and its mechanism.","authors":"Ping Liu, Zhaohui Meng, Lei Zhang, Guangjuan Li, Hui Huang","doi":"10.1097/FJC.0000000000001724","DOIUrl":null,"url":null,"abstract":"<p><p>HDAC4 is highly expressed in patients with essential hypertension and is closely related to myocardial injury. Therefore, this study aims to explore the effects and mechanisms of HDAC4 on cardiac injury in spontaneously hypertensive rats, with the aim of providing new directions for the diagnosis and treatment of hypertensive myocardial disease.Compared with WKY group, the blood pressure, myocardial injury markers, myocardial cell apoptosis rate, cleaved-caaspase9 protein, TNF-α, HDAC4 mRNA, HDAC4 protein, IL-6, cleaved-caaspase3 protein, MDA, β-catenin protein, IL-1β, Wnt3a protein levels in SHR group significantly increased (P<0.05), while LVEF and SOD levels significantly decreased (P<0.05); interfering with HDAC4 expression can reduce the cardiomyocyte apoptosis rate, cleaved-caspase9 protein, TNF-α, HDAC4 mRNA, HDAC4 protein, IL-6, cleaved-caspase3 protein, MDA, β-catenin protein, IL-1β, and Wnt3a protein levels, and increase LVEF and SOD levels; Overexpression of HDAC4 has the opposite effect. HDAC4 may play a role in regulating cardiac injury in SHR rats by regulating β-catenin signaling pathway.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cardiovascular Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/FJC.0000000000001724","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
HDAC4 is highly expressed in patients with essential hypertension and is closely related to myocardial injury. Therefore, this study aims to explore the effects and mechanisms of HDAC4 on cardiac injury in spontaneously hypertensive rats, with the aim of providing new directions for the diagnosis and treatment of hypertensive myocardial disease.Compared with WKY group, the blood pressure, myocardial injury markers, myocardial cell apoptosis rate, cleaved-caaspase9 protein, TNF-α, HDAC4 mRNA, HDAC4 protein, IL-6, cleaved-caaspase3 protein, MDA, β-catenin protein, IL-1β, Wnt3a protein levels in SHR group significantly increased (P<0.05), while LVEF and SOD levels significantly decreased (P<0.05); interfering with HDAC4 expression can reduce the cardiomyocyte apoptosis rate, cleaved-caspase9 protein, TNF-α, HDAC4 mRNA, HDAC4 protein, IL-6, cleaved-caspase3 protein, MDA, β-catenin protein, IL-1β, and Wnt3a protein levels, and increase LVEF and SOD levels; Overexpression of HDAC4 has the opposite effect. HDAC4 may play a role in regulating cardiac injury in SHR rats by regulating β-catenin signaling pathway.
期刊介绍:
Journal of Cardiovascular Pharmacology is a peer reviewed, multidisciplinary journal that publishes original articles and pertinent review articles on basic and clinical aspects of cardiovascular pharmacology. The Journal encourages submission in all aspects of cardiovascular pharmacology/medicine including, but not limited to: stroke, kidney disease, lipid disorders, diabetes, systemic and pulmonary hypertension, cancer angiogenesis, neural and hormonal control of the circulation, sepsis, neurodegenerative diseases with a vascular component, cardiac and vascular remodeling, heart failure, angina, anticoagulants/antiplatelet agents, drugs/agents that affect vascular smooth muscle, and arrhythmias.
Appropriate subjects include new drug development and evaluation, physiological and pharmacological bases of drug action, metabolism, drug interactions and side effects, application of drugs to gain novel insights into physiology or pathological conditions, clinical results with new and established agents, and novel methods. The focus is on pharmacology in its broadest applications, incorporating not only traditional approaches, but new approaches to the development of pharmacological agents and the prevention and treatment of cardiovascular diseases. Please note that JCVP does not publish work based on biological extracts of mixed and uncertain chemical composition or unknown concentration.